@nsayeghmd Profile picture

Nicolas Sayegh, MD

@nsayeghmd

PGY-2 @UTSWInternalMed | GU Oncology Research Fellow @HuntsmanCancer @UUtah

Similar User
Georges Gebrael photo

@ggebraelmd

Guru P. Sonpavde, MD photo

@sonpavde

Neeraj Agarwal, MD, FASCO photo

@neerajaiims

Andrea Necchi photo

@AndreaNecchi

Paulo G Bergerot photo

@PauloBergerot

Dana-Farber Lank Center for Genitourinary Oncology photo

@DanaFarber_GU

Matt Galsky photo

@MattGalsky

Chris Labaki photo

@Chrislabaki1

Christopher Sweeney, MBBS photo

@ChrisSweens1

Rana McKay, MD, FASCO photo

@DrRanaMcKay

Nazli Dizman photo

@NazliDizman

Pedro C Barata, MD MSc FACP photo

@PBarataMD

Umang Swami photo

@umangtalking

Alex Chehrazi-Raffle, MD photo

@arafflemd

Amanda Nizam, MD photo

@AmandaNizamMD

Nicolas Sayegh, MD Reposted

Voluntary withdrawal of sacituzumab govitecan in pretreated advanced bladder cancer occurred today. Accelerated approval relied on TROPICS4 which was negative for OS. The May 30th press release stated activity but also a toxicity signal. Details awaited ca.finance.yahoo.com/news/gilead-vo…


Nicolas Sayegh, MD Reposted

A must to listen, fantastic talk for young investigators by @neerajaiims on : The Art of Patient Enrollment in Genitourinary Oncology Clinical Trials @SWOG @huntsmancancer @OncoAlert

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Nicolas Sayegh, MD Reposted

Woke up to this incredible news from the #TALAPRO2 study. Hugely proud of @neerajaiims @huntsmancancer for leading the 1st study to show an OS benefit with ARPI + PARP in mCRPC. Note PR cites OS benefit in both all comers (cohort 1) & in pts with HRR mutations (cohort 2).…


Nicolas Sayegh, MD Reposted

🔶#Residencyand #Fellowshipmatch present specific challenges to #IMGs - IMGs have fewer opportunities to match into academic programs (Reddy et al. J Jan Intern Med 2021) - Non-US citizen IMG applicants are viewed by fellowship program directors as the most disadvantaged…

Tweet Image 1

Nicolas Sayegh, MD Reposted

Intensification & de-intensification in treatment of mRCC #kidneycancer 👉Fantastic talk by the master @montypal at @urologysummit #IUCS24 👉his take on adjuvant and ph3 trials👇& de-intensification of Rx with microbiome modulation👇@OncoAlert @urotoday @kidneycan @KidneyCancer

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Nicolas Sayegh, MD Reposted

Front row for a terrific talk by @neerajaiims on T-cell engagers in #prostatecancer in #ESMO24 @myESMO 👇🏻 ⭐️ Promising activity but more data needed ⭐️Potential ways to improve their efficacy @Huntsman_GU @NeliMUlrich @umangtalking @maughanonc @urotoday @OncoAlert @PCF_Science

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Nicolas Sayegh, MD Reposted

Thrilled to attend @montypal's enlightening talk on gut bacteria and cancer at @UofUHealth!! 🌟 Looking forward to gaining new insights! @neerajaiims @huntsmancancer @umangtalking @Huntsman_GU @chadihc98 @bev_chigarira @NeliMUlrich

Tweet Image 1
Tweet Image 2
Tweet Image 3

Nicolas Sayegh, MD Reposted

Front row to watch @montypal ‘s terrific internal medicine grand round on gut bacteria and cancer! @neerajaiims @Huntsman_GU @umangtalking @ziremozay @ggebraelmd @UofUInternalMed @NeliMUlrich @maughanonc @nsayeghmd

Tweet Image 1
Tweet Image 2

Nicolas Sayegh, MD Reposted

Just in @Annals_Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 @urotoday @OncoAlert @kidneycan @huntsmancancer

Tweet Image 1
Tweet Image 2
Tweet Image 3

Nicolas Sayegh, MD Reposted

Just in👉bit.ly/3AMRBec Real world claims analysis of 10 AEs in #mCSPC. AE rates⬆️over time across Rx groups. Most AE rates with ADT+ARPIs were comparable to ADT+NSAA & ADT alone. ADT+docetaxel had⬆️rates of 7 AEs. Sexual function AE didn't differ between Rx. @OncoAlert

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Nicolas Sayegh, MD Reposted

We have an important announcement about our Internal Medicine Residency program, a development that will position @UTSWMedCenter as having the second largest internal medicine residency program in the nation! utsouthwestern.edu/departments/in…


Nicolas Sayegh, MD Reposted

@neerajaiims gives an excellent talk on tips, tricks & tremendous scope of #SoMe in oncology for Meded, caregivers, researchers, patient advocates, patients with 🌎#WorldGU24 @GUconference Kudos to him for his significant contributions to #ASCODailyNews as Editor-in-Chief!

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Nicolas Sayegh, MD Reposted

New Study Alert! 🚨 "Cardiovascular Diseases Increase Cancer Mortality in Adults: NHANES‐Continuous Study," is now published in @JAHA_AHA We delve into the cardiovascular risks that young cancer patients face. 🩺#CardioOnc Funded by @AHAScience #SFRN. @OelsayedMD 1/4

Tweet Image 1

Nicolas Sayegh, MD Reposted

(1/4) Tweetorial for our latest paper on body composition’s influence on the therapeutic index with ARSI in @pcan_journal shorturl.at/UFqay This work was supported by a @ConquerCancerFd YIA and established our ongoing research program @MDAndersonNews

Tweet Image 1

Nicolas Sayegh, MD Reposted

(2/4) Steroidogenesis has roles in muscle, fat, and PCa. We studied how inherited variants in steroidogenic genes influenced body composition at time of mCRPC. We found differences in body composition by genotype in AKR1C3, CYP17A1, and SRD5A2 SNPs

Tweet Image 1

Nicolas Sayegh, MD Reposted

Great representation from @utswcancer @UTSWMedCenter at #BESTOFASCO 2024! Awesome to have our trainees here learning newest cancer updates! Thanks for coming @nsayeghmd !

⚪️Best of #ASCO 2024 in #Dallas TX @TiansterZhang comprehensively presenting latest practice-changing data about #kidneycancer and #bladdercancer @UTSWInternalMed @UTSWMedCenter

Tweet Image 1


⚪️Best of #ASCO 2024 in #Dallas TX @TiansterZhang comprehensively presenting latest practice-changing data about #kidneycancer and #bladdercancer @UTSWInternalMed @UTSWMedCenter

Tweet Image 1

Nicolas Sayegh, MD Reposted

Happy to share our recently published work in @JAMANetworkOpen co-lead w/ @YeonjungJoHCI showing ⬇️ NGS testing rates in pts w/ metastatic prostate & urothelial cancers👉Grateful for terrific mentorship from @umangtalking @neerajaiims & team @ggebraelmd @urotoday @OncoAlert

Tweet Image 1


Nicolas Sayegh, MD Reposted

Happy to share our recently published work in @JAMANetworkOpen co-lead w/ @YeonjungJoHCI showing ⬇️ NGS testing rates in pts w/ metastatic prostate & urothelial cancers👉Grateful for terrific mentorship from @umangtalking @neerajaiims & team @ggebraelmd @urotoday @OncoAlert

Tweet Image 1

Just in @JAMANetworkOpen 👉 Unacceptablely low rates of NGS testing in metastatic #ProstateCancer #bladdercancer in real world pts (worse in Black & Hispanic pts)@flatironhealth👇Proud of our postdoc, Chadi @chadihc98 , Yeonjung @yeonjungjohci, George @ggebraelmd & team👇…

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4


Nicolas Sayegh, MD Reposted

Just in @JAMANetworkOpen 👉 Unacceptablely low rates of NGS testing in metastatic #ProstateCancer #bladdercancer in real world pts (worse in Black & Hispanic pts)@flatironhealth👇Proud of our postdoc, Chadi @chadihc98 , Yeonjung @yeonjungjohci, George @ggebraelmd & team👇…

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Loading...

Something went wrong.


Something went wrong.